Nettis E, et al. - In a real-life setting, the efficacy and safety of omalizumab in elderly (aged ≥65 years) patients with nonsedating H₁-antihistamine–refractory chronic spontaneous urticaria (CSU) was determined. For this patient population, omalizumab was shown to be a well-tolerated and effective therapy.